Quince Therapeutics stopped development of its eDSP (dexamethasone sodium phosphate encapsulated in autologous erythrocytes) program after the phase III Neat trial in ataxia‑telangiectasia failed to meet its primary and key secondary endpoints. The company released top‑line results showing no statistically significant improvement versus placebo, and shares plunged roughly 90% on the news. Analysts called the core value driver impaired and the program effectively scrapped, forcing Quince to wind down the asset and reassess. The outcome removes a principal clinical catalyst and underscores the risk of late‑stage readouts in small biotech franchises.